Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow

Ann Thor, Mary Jo Viglione, Noriaki Ohuchi, Jean Simpson, Ronald Steis, John Cousar, Marc E Lippman, Donald W. Kufe, Jeffrey Schlom

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Twenty percent (n = 6) of Stage III or IV breast cancer patients (n = 30) had bone marrow metastases detected in bilateral bone marrow biopsy/aspiration preparations using standard histologic preparations. Each metastasis was also detected by four separate monoclonal antibodies (MAbs) which recognize breast carcinoma associated antigens (DF3, anti-EMA, HMFG-2, and CAM5.2). These MAbs were then utilized to stain other bone marrow preparations (n = 81) to determine their utility for the detection of micrometastatic breast carcinoma. MAbs HMFG-2, anti-EMA, and DF3 were each strongly reactive with bone marrows containing histologically-evident metastatic breast carcinoma (18/18). These anti-epithelial membrane antigen MAbs, however, were also reactive with rare plasma cells and immature cells (as well as cell clusters) in some of the control bone marrow samples tested, including those from normal patients and patients with hematologic disorders. They also reacted with some of the preparations from patients with leukemia and lymphoma, and with uninvolved marrows from patients with non-epithelial malignancies. The anti-keratin MAb CAM5.2, in contrast, reacted with 83% (15/18) breast cancer metastases and failed to stain any cells in the various categories of control marrow preparations. These data suggested that MAb CAM5.2 might be utilized to immunohistochemically differentiate micrometastatic breast carcinoma from immature myeloid or erythroid elements. Each MAb was then reacted with histologically uninvolved marrow preparations from the remaining 24 of 30 breast cancer patients in an attempt to identify occult breast carcinoma metastases. While MAbs HMFG-2, DF3, and anti-EMA demonstrated reactive cells in some of these marrows, this reactivity was similar to that seen with control preparations. MAb CAM5.2, in contrast, was negative with all specimens. These data suggest that MAb CAM5.2 may be a useful immunologic probe for the detection and confirmation of metastatic breast carcinoma in bone marrow, while more caution must be employed in the interpretation of results obtained using MAbs anti-EMA, DF3, and HMFG-2.

Original languageEnglish
Pages (from-to)133-145
Number of pages13
JournalBreast Cancer Research and Treatment
Volume11
Issue number2
DOIs
StatePublished - May 1 1988
Externally publishedYes

Fingerprint

Bone Marrow
Monoclonal Antibodies
Breast Neoplasms
Neoplasm Metastasis
Coloring Agents
Tumor-Associated Carbohydrate Antigens
Mucin-1
Needle Biopsy
Keratins
Plasma Cells
Lymphoma
Leukemia
CAM 5.2 antigen
Neoplasms

Keywords

  • bone marrow
  • breast carcinoma
  • cytokeratin
  • epithelial antigens
  • immunohistochemistry
  • micrometastasis
  • monoclonal antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thor, A., Viglione, M. J., Ohuchi, N., Simpson, J., Steis, R., Cousar, J., ... Schlom, J. (1988). Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Research and Treatment, 11(2), 133-145. https://doi.org/10.1007/BF01805837

Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. / Thor, Ann; Viglione, Mary Jo; Ohuchi, Noriaki; Simpson, Jean; Steis, Ronald; Cousar, John; Lippman, Marc E; Kufe, Donald W.; Schlom, Jeffrey.

In: Breast Cancer Research and Treatment, Vol. 11, No. 2, 01.05.1988, p. 133-145.

Research output: Contribution to journalArticle

Thor, A, Viglione, MJ, Ohuchi, N, Simpson, J, Steis, R, Cousar, J, Lippman, ME, Kufe, DW & Schlom, J 1988, 'Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow', Breast Cancer Research and Treatment, vol. 11, no. 2, pp. 133-145. https://doi.org/10.1007/BF01805837
Thor, Ann ; Viglione, Mary Jo ; Ohuchi, Noriaki ; Simpson, Jean ; Steis, Ronald ; Cousar, John ; Lippman, Marc E ; Kufe, Donald W. ; Schlom, Jeffrey. / Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. In: Breast Cancer Research and Treatment. 1988 ; Vol. 11, No. 2. pp. 133-145.
@article{8fc072adf71a40d190bfb4d3b77501cb,
title = "Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow",
abstract = "Twenty percent (n = 6) of Stage III or IV breast cancer patients (n = 30) had bone marrow metastases detected in bilateral bone marrow biopsy/aspiration preparations using standard histologic preparations. Each metastasis was also detected by four separate monoclonal antibodies (MAbs) which recognize breast carcinoma associated antigens (DF3, anti-EMA, HMFG-2, and CAM5.2). These MAbs were then utilized to stain other bone marrow preparations (n = 81) to determine their utility for the detection of micrometastatic breast carcinoma. MAbs HMFG-2, anti-EMA, and DF3 were each strongly reactive with bone marrows containing histologically-evident metastatic breast carcinoma (18/18). These anti-epithelial membrane antigen MAbs, however, were also reactive with rare plasma cells and immature cells (as well as cell clusters) in some of the control bone marrow samples tested, including those from normal patients and patients with hematologic disorders. They also reacted with some of the preparations from patients with leukemia and lymphoma, and with uninvolved marrows from patients with non-epithelial malignancies. The anti-keratin MAb CAM5.2, in contrast, reacted with 83{\%} (15/18) breast cancer metastases and failed to stain any cells in the various categories of control marrow preparations. These data suggested that MAb CAM5.2 might be utilized to immunohistochemically differentiate micrometastatic breast carcinoma from immature myeloid or erythroid elements. Each MAb was then reacted with histologically uninvolved marrow preparations from the remaining 24 of 30 breast cancer patients in an attempt to identify occult breast carcinoma metastases. While MAbs HMFG-2, DF3, and anti-EMA demonstrated reactive cells in some of these marrows, this reactivity was similar to that seen with control preparations. MAb CAM5.2, in contrast, was negative with all specimens. These data suggest that MAb CAM5.2 may be a useful immunologic probe for the detection and confirmation of metastatic breast carcinoma in bone marrow, while more caution must be employed in the interpretation of results obtained using MAbs anti-EMA, DF3, and HMFG-2.",
keywords = "bone marrow, breast carcinoma, cytokeratin, epithelial antigens, immunohistochemistry, micrometastasis, monoclonal antibodies",
author = "Ann Thor and Viglione, {Mary Jo} and Noriaki Ohuchi and Jean Simpson and Ronald Steis and John Cousar and Lippman, {Marc E} and Kufe, {Donald W.} and Jeffrey Schlom",
year = "1988",
month = "5",
day = "1",
doi = "10.1007/BF01805837",
language = "English",
volume = "11",
pages = "133--145",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow

AU - Thor, Ann

AU - Viglione, Mary Jo

AU - Ohuchi, Noriaki

AU - Simpson, Jean

AU - Steis, Ronald

AU - Cousar, John

AU - Lippman, Marc E

AU - Kufe, Donald W.

AU - Schlom, Jeffrey

PY - 1988/5/1

Y1 - 1988/5/1

N2 - Twenty percent (n = 6) of Stage III or IV breast cancer patients (n = 30) had bone marrow metastases detected in bilateral bone marrow biopsy/aspiration preparations using standard histologic preparations. Each metastasis was also detected by four separate monoclonal antibodies (MAbs) which recognize breast carcinoma associated antigens (DF3, anti-EMA, HMFG-2, and CAM5.2). These MAbs were then utilized to stain other bone marrow preparations (n = 81) to determine their utility for the detection of micrometastatic breast carcinoma. MAbs HMFG-2, anti-EMA, and DF3 were each strongly reactive with bone marrows containing histologically-evident metastatic breast carcinoma (18/18). These anti-epithelial membrane antigen MAbs, however, were also reactive with rare plasma cells and immature cells (as well as cell clusters) in some of the control bone marrow samples tested, including those from normal patients and patients with hematologic disorders. They also reacted with some of the preparations from patients with leukemia and lymphoma, and with uninvolved marrows from patients with non-epithelial malignancies. The anti-keratin MAb CAM5.2, in contrast, reacted with 83% (15/18) breast cancer metastases and failed to stain any cells in the various categories of control marrow preparations. These data suggested that MAb CAM5.2 might be utilized to immunohistochemically differentiate micrometastatic breast carcinoma from immature myeloid or erythroid elements. Each MAb was then reacted with histologically uninvolved marrow preparations from the remaining 24 of 30 breast cancer patients in an attempt to identify occult breast carcinoma metastases. While MAbs HMFG-2, DF3, and anti-EMA demonstrated reactive cells in some of these marrows, this reactivity was similar to that seen with control preparations. MAb CAM5.2, in contrast, was negative with all specimens. These data suggest that MAb CAM5.2 may be a useful immunologic probe for the detection and confirmation of metastatic breast carcinoma in bone marrow, while more caution must be employed in the interpretation of results obtained using MAbs anti-EMA, DF3, and HMFG-2.

AB - Twenty percent (n = 6) of Stage III or IV breast cancer patients (n = 30) had bone marrow metastases detected in bilateral bone marrow biopsy/aspiration preparations using standard histologic preparations. Each metastasis was also detected by four separate monoclonal antibodies (MAbs) which recognize breast carcinoma associated antigens (DF3, anti-EMA, HMFG-2, and CAM5.2). These MAbs were then utilized to stain other bone marrow preparations (n = 81) to determine their utility for the detection of micrometastatic breast carcinoma. MAbs HMFG-2, anti-EMA, and DF3 were each strongly reactive with bone marrows containing histologically-evident metastatic breast carcinoma (18/18). These anti-epithelial membrane antigen MAbs, however, were also reactive with rare plasma cells and immature cells (as well as cell clusters) in some of the control bone marrow samples tested, including those from normal patients and patients with hematologic disorders. They also reacted with some of the preparations from patients with leukemia and lymphoma, and with uninvolved marrows from patients with non-epithelial malignancies. The anti-keratin MAb CAM5.2, in contrast, reacted with 83% (15/18) breast cancer metastases and failed to stain any cells in the various categories of control marrow preparations. These data suggested that MAb CAM5.2 might be utilized to immunohistochemically differentiate micrometastatic breast carcinoma from immature myeloid or erythroid elements. Each MAb was then reacted with histologically uninvolved marrow preparations from the remaining 24 of 30 breast cancer patients in an attempt to identify occult breast carcinoma metastases. While MAbs HMFG-2, DF3, and anti-EMA demonstrated reactive cells in some of these marrows, this reactivity was similar to that seen with control preparations. MAb CAM5.2, in contrast, was negative with all specimens. These data suggest that MAb CAM5.2 may be a useful immunologic probe for the detection and confirmation of metastatic breast carcinoma in bone marrow, while more caution must be employed in the interpretation of results obtained using MAbs anti-EMA, DF3, and HMFG-2.

KW - bone marrow

KW - breast carcinoma

KW - cytokeratin

KW - epithelial antigens

KW - immunohistochemistry

KW - micrometastasis

KW - monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=0023914498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023914498&partnerID=8YFLogxK

U2 - 10.1007/BF01805837

DO - 10.1007/BF01805837

M3 - Article

C2 - 2456802

AN - SCOPUS:0023914498

VL - 11

SP - 133

EP - 145

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -